Molecular-based diagnostic kits manufacturer Jiangsu Bioperfectus Technologies Co – based in Taizhou city, in China's East Jiangsu province – is currently working at full capacity to guarantee market supplies, executive vice president Liu Zhonghua said on Oct 18.
The Shanghai stock exchange-listed hi-tech enterprise – at the cutting-edge of moves to fight the COVID-19 pandemic – has been continuing to independently develop core technologies, Liu noted.
He added that the group has been providing timely supplies of diagnostic reagents to all over the world for COVID-19 prevention and control.
Its operations are widely seen as being the epitome of wider efforts made by enterprises in the Taizhou Medical High-tech Zone – located in the city and home to more than 1,200 pharmaceutical enterprises.
Xu Yongqian, a Party chief of the zone's new drug applications center, said vigorous efforts had been made to help local enterprises obtain approval for drugs and medical devices over the past decade – which is even more the case today.
"We intervene in advance, participate in the whole process and offer all-round services – providing enterprises with professional registration and applications services and helping the biopharmaceutical industry in the Taizhou Medical High-tech Zone to achieve high-quality growth," Xu added.
The traditional Chinese medical center in the Taizhou Institute for Drug Control provides tailored services to local pharma manufacturing plants. It has also made technological breakthroughs in aflatoxin and DNA molecular sequencing.
Xu Jiabing, an inspector with the center, said he felt a heavy responsibility to promote the Healthy China initiative and TCM inheritance and innovation after studying the report of the 20th CPC National Congress.